A Phase III Randomized Clinical Trial of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
Locally advanced esophageal squamous cell carcinoma. T2-4N0-1M0-1a,TxN1M0-1a，TxNxM1a
（according to AJCC2002）
Eligible recurrent patients with esophageal cancer will first be stratified by nodal staging
(N0 or N1), then randomized to 2 arms at 1:1 ratio.
Chemoradiotherapy with cisplatin and 5-fluorouracil for 4 cycles.
Chemoradiotherapy with weekly paclitaxel and 5-fluorouracil for 5 weeks followed by adjuvant
chemotherapy for 2 cycles.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
1-yr overall survivals
Kuai Le Zhao, M.D.
China: Ethics Committee